Pharmaceutical Companies

The withdrawal changes the immediate US regulatory path for the ES-SCLC indication, but the ongoing Phase III programme provides the companies with another source of clinical data.

The collaboration comes as pharmaceutical developers explore alternative delivery routes for biologic medicines, which can present formulation and administration challenges because of their molecular size and complexity.

Shanghai-based Raas disclosed the proposed acquisition in a financial filing, stating that it plans to acquire a 100% stake in Boehringer Ingelheim Biopharmaceuticals in China.

The announcement was made at the Riyadh Global Medical Biotechnology Summit (RGMBS), building on a collaboration established after Saudi Arabia’s first gene therapy infusion in 2024.

The agreement brings together BoomRay’s expertise in radioligand therapy development and Novartis’ global capabilities in radiopharmaceutical research and commercialisation.

The collaboration will assess selected targets for several therapeutic approaches, including antibody-drug conjugates (ADCs), multispecific antibodies and T cell engagers (TcEs).

Currently, about five in 10 women diagnosed with breast cancer in Africa survive for at least five years after diagnosis.

Following completion of the acquisition, ITM shareholders are expected to hold 23.7% of Telix, while existing Telix shareholders will retain 76.3%.

The agreement covers licensing, development, manufacturing and commercialisation of the candidate, which is currently in the early stages of development.

The arrangement gives Ona Therapeutics access to WuXi XDC’s capabilities across ADC development and manufacturing as it advances the candidate towards clinical development.